Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | FAAH | O00519 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26108043 | 0.78 | TSHR (0.31) | TSHRCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL28343786 | 0.76 | HCAR2 (0.39) | TSHRALDH1A1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL7394588 | 0.76 | TSHR (0.32) | TSHR | |
| SCHEMBL4412 | 0.76 | — | — | |
| SCHEMBL429885 | 0.75 | TSHR (0.67) | TSHRALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL317108 | 0.75 | TSHR (0.67) | TSHRALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL10622212 | 0.75 | TSHR (0.67) | TSHRALDH1A1HPGDSMN1; SMN2CYP2C9 | |
| SCHEMBL317107 | 0.75 | TSHR (0.67) | TSHRALDH1A1HPGDSMN1; SMN2 | |
| Azaserine SCHEMBL3312110 | 0.75 | SLC1A5 (0.38) | CYP1A2CYP2C9CYP2C19 | |
| Azaserine SCHEMBL8862 | 0.75 | SLC1A5 (0.38) | CYP1A2CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250092008-A1 | PROCESS FOR MAKING AN EP4 ANTAGONIST | ONO PHARMACEUTICAL CO., LTD. (JP) | 2025-03-20 | — | — | US | disclosed |
| EP-4384509-A1 | PROCESS FOR MAKING AN EP4 ANTAGONIST | ONO Pharmaceutical Co., Ltd. (JP) | 2024-06-19 | — | — | EP | disclosed |
| WO-2023017813-A1 | PROCESS FOR MAKING AN EP4 ANTAGONIST | ONO PHARMACEUTICAL CO., LTD. (JP) | 2023-02-16 | — | — | WO | disclosed |
| CN-115028570-A | Preparation method of (1R, 2S, 5S) -6, 6-dimethyl-3-azabicyclo [3, 1, 0] hexyl-2-carboxylate | 浙江新和成股份有限公司 | 2022-09-09 | — | — | CN | disclosed |
| EP-1783111-B1 | METHOD FOR PRODUCING OPTICALLY ACTIVE CYCLOPROPANECARBOXYLATE COMPOUND | SUMITOMO CHEMICAL CO (JP) | 2015-04-08 | — | — | EP | disclosed |
| EP-2781522-A1 | OPTICALLY ACTIVE BISOXAZOLINE COMPOUND, ASYMMETRIC CATALYST, AND METHOD FOR PRODUCING OPTICALLY ACTIVE CYCLOPROPANE COMPOUND USING SAID CATALYST | Sumitomo Chemical Company, Limited (JP) | 2014-09-24 | — | — | EP | disclosed |
| CN-101506142-B | Process for production of trans-2,2-dimethyl- 3-formylcyclopropane carboxylic acid ester | SUMITOMO CO LTD | 2013-04-17 | — | — | CN | disclosed |
| US-8409831-B2 | Method for producing (1S,2R)-2-chloro-2-fluorocyclopropanecarboxylic acid | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2013-04-02 | — | — | US | disclosed |
| EP-2311974-B1 | PROCESS FOR PRODUCING (1S,2R)-2-CHLORO-2-FLUOROCYCLOPROPANECARBOXYLIC ACID | SUMITOMO CHEMICAL CO (JP) | 2012-12-19 | — | — | EP | disclosed |
| EP-1607136-B1 | OPTICALLY ACTIVE COPPER CATALYST COMPOSITION | SUMITOMO CHEMICAL CO (JP) | 2012-05-23 | — | — | EP | disclosed |
| CN-1852887-A | Process for producing optically active cyclopropane compound and asymmetric copper complex for use in the same | SUMITOMO CHEMICAL CO (JP) | 2006-10-25 | — | — | CN | disclosed |
| US-20060211879-A1 | Optically active copper catalyst composition | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2006-09-21 | — | — | US | disclosed |
| US-20060149077-A1 | Optically active bisoxazoline compounds, process for production of the same and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2006-07-06 | — | — | US | disclosed |
| CN-1798609-A | optically active copper catalyst composition | SUMITOMO CHEMICAL CO (JP) | 2006-07-05 | — | — | CN | disclosed |
| EP-1674445-A1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE CYCLOPROPANE COMPOUND AND ASYMMETRIC COPPER COMPLEX FOR USE IN THE SAME | Sumitomo Chemical Company, Limited (JP) | 2006-06-28 | — | — | EP | disclosed |
| EP-1607136-A1 | OPTICALLY ACTIVE COPPER CATALYST COMPOSITION | Sumitomo Chemical Company, Limited (JP) | 2005-12-21 | — | — | EP | disclosed |
| EP-1593674-A1 | OPTICALLY ACTIVE BISOXAZOLINE COMPOUNDS, PROCESS FOR PRODUCTION OF THE SAME AND USE THEREOF | Sumitomo Chemical Company, Limited (JP) | 2005-11-09 | — | — | EP | disclosed |
| CN-1173922-C | Process for producing opitically active cyclopropanecaboxylic acid esters | 住友化学工业株式会社 | 2004-11-03 | — | — | CN | disclosed |
| EP-0891965-A1 | Process for producing optically active cyclopropanecarboxylic acid esters | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 1999-01-20 | — | — | EP | disclosed |
| CN-1205326-A | Process for producing opitically active cyclopropanecaboxylic acid esters | SUMITOMO CHEMICAL CO (JP) | 1999-01-20 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060149077-A1 | Optically active bisoxazoline compounds, process for production of the same and use thereof | ACSL3, ADSL, SQLE | TSHR 3816/4885ALDH1A1 897/4885HPGD 1596/4885 |
| US-20250092008-A1 | PROCESS FOR MAKING AN EP4 ANTAGONIST | PTGER4, LTB4R2, EPB41 | TSHR 1750/4885ALDH1A1 1405/4885HPGD 120/4885 |
| US-20060211879-A1 | Optically active copper catalyst composition | CCNL2, HACL2, ARL1 | TSHR 2249/4885ALDH1A1 205/4885HPGD 4128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.